English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Platelet-rich plasma (PRP) is plasma with high concentration of platelets compared with whole blood. The therapeutic effect of platelet-rich plasma is based on the effect of growth factors contained in α-granules of platelets. Transforming growth factor β1 (TGF-β1) is a growth factor of TGF-β superfamily which an amount is considerable in platelets and have the important role in musculoskeletal system regeneration. MATERIALS AND METHODS. In this study using the ELISA, we determined the content of TGF-β1 in platelet-rich plasma in 14 patients with various musculoskeletal disorders, aged from 21 to 79. RESULTS. The level of TGF-β1 in platelet-rich plasma was found to be 194.57 ± 25.76 ng/ml, which was 30 times higher than its control content (platelet-poor plasma), where its content was 6.52 ± 3.26 ng/ml. No statistically significant difference was observed between TGF-β1 levels in platelet-rich plasma in the patients of different age and gender. CONCLUSIONS. It has been established that platelet-rich plasma can serve as a source of TGF-β1 for therapeutic purposes. TGF-β1 content in platelet-rich plasma has been shown to be independent of gender and age and, therefore, a wide range of patients may be treated with it.

TGF-β1 level in platelet-rich plasma in patients with diseases and injuries of the musculoskeletal system